JP2005511612A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511612A5
JP2005511612A5 JP2003542191A JP2003542191A JP2005511612A5 JP 2005511612 A5 JP2005511612 A5 JP 2005511612A5 JP 2003542191 A JP2003542191 A JP 2003542191A JP 2003542191 A JP2003542191 A JP 2003542191A JP 2005511612 A5 JP2005511612 A5 JP 2005511612A5
Authority
JP
Japan
Prior art keywords
valaciclovir hydrochloride
anhydrous
anhydrous crystalline
spectrometer
resolution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003542191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/033926 external-priority patent/WO2003040145A1/en
Publication of JP2005511612A publication Critical patent/JP2005511612A/ja
Publication of JP2005511612A5 publication Critical patent/JP2005511612A5/ja
Pending legal-status Critical Current

Links

JP2003542191A 2001-11-05 2002-10-23 塩酸バラシクロビルの無水結晶形 Pending JP2005511612A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33331301P 2001-11-05 2001-11-05
PCT/US2002/033926 WO2003040145A1 (en) 2001-11-05 2002-10-23 Anhydrous crystal form of valaciclovir hydrochloride

Publications (2)

Publication Number Publication Date
JP2005511612A JP2005511612A (ja) 2005-04-28
JP2005511612A5 true JP2005511612A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=23302261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542191A Pending JP2005511612A (ja) 2001-11-05 2002-10-23 塩酸バラシクロビルの無水結晶形

Country Status (10)

Country Link
US (2) US20040197396A1 (cg-RX-API-DMAC7.html)
EP (1) EP1453834A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005511612A (cg-RX-API-DMAC7.html)
AU (1) AU2002348022B2 (cg-RX-API-DMAC7.html)
CA (1) CA2465420A1 (cg-RX-API-DMAC7.html)
FR (1) FR2831885A1 (cg-RX-API-DMAC7.html)
GB (1) GB2383038B (cg-RX-API-DMAC7.html)
GR (1) GR1004358B (cg-RX-API-DMAC7.html)
IT (1) ITRM20020555A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003040145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN105753868B (zh) * 2016-04-12 2017-08-01 浙江理工大学 一种盐酸伐昔洛韦的半水合物及其制备方法
CN112176011B (zh) * 2020-10-26 2022-10-18 辰欣药业股份有限公司 一种酶催化制备盐酸伐昔洛韦的方法
CN116754538B (zh) * 2023-06-15 2024-05-07 深圳市新阳唯康科技有限公司 一种阿昔洛韦软膏的晶型定量方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
JP2007522130A (ja) * 2004-01-21 2007-08-09 テバ ファーマシューティカル インダストリーズ リミティド 塩酸バラシクロビルの調製方法
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Similar Documents

Publication Publication Date Title
JP2023145481A5 (cg-RX-API-DMAC7.html)
JP2024001023A5 (cg-RX-API-DMAC7.html)
JP2016065042A5 (cg-RX-API-DMAC7.html)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
HRP20241443T1 (hr) Kristalni oblici 7-klor-2-(4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamida
CA2608018A1 (en) Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
JP2010506932A5 (cg-RX-API-DMAC7.html)
RU2007141198A (ru) Кристаллическая форма малеата азенапина
RU2598606C3 (ru) Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она
IL167168A (en) Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
RU2008120338A (ru) Полиморфы с-met/hgfr ингибитора
JP2021517111A5 (cg-RX-API-DMAC7.html)
JP2014526498A5 (cg-RX-API-DMAC7.html)
HRP20121028T1 (hr) Kristalni oblici febuksostata
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
RU2012146517A (ru) Соли ральтегравира и их кристаллические формы
JP2021513944A5 (cg-RX-API-DMAC7.html)
RU2009116260A (ru) Полиморфные модификации никотиновых промежуточных продуктов
JP2017532279A5 (cg-RX-API-DMAC7.html)
JP2006249089A5 (cg-RX-API-DMAC7.html)
IL273896B1 (en) Crystalline forms of 1,2,4-oxadiazole-3-methyl-1,2-dione
JP2008516004A5 (cg-RX-API-DMAC7.html)
KR950010910A (ko) 내포 복합체
JP2002308895A5 (cg-RX-API-DMAC7.html)